SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?


To: Mama Bear who wrote (981)12/15/1997 12:45:00 AM
From: Druss  Respond to of 7041
 
Barbara--Regarding the stock buy back.
Vivus announced a while back the same sort of thing when their stock price was taking a pounding. I have seen no evidence that they have done so. I currently have no position in this stock but may short tommorrow. If I were long the wording of that 'buy back' would raise alarms for me. The wording of that post indicates the company is playing to the stock price. To me if a company feels the best place to put assets is in the stock then they should say 'will' buy back. As you have pointed out they have committed themselves to nothing with this press release.
All the Best
Druss



To: Mama Bear who wrote (981)12/15/1997 4:25:00 AM
From: Bill Wexler  Read Replies (1) | Respond to of 7041
 
Barb...I've been reading some of the responses you got on this thread.

Like I said before, ZONA looks like another home run. The stock buyback announcement clinched it for me.

Isn't it amazing how when these scam companies unravel, they always seem to follow the same pattern (shrill press releases, empty promises of stock buybacks 30 minutes after the stock takes a pounding, etc. etc.)

Short at 30, 26, 24...will continue shorting as long as I can find shares.



To: Mama Bear who wrote (981)12/15/1997 9:29:00 AM
From: Dauntless  Read Replies (1) | Respond to of 7041
 
Barbara,

RE: "But I'd bet that they have more failures in deals like this than success. "

I'm pretty certain that Schering's track record in deals where Phase III clinicals are complete & the data available for review is pretty good. I'd guess 75% or higher. Also, don't forget that many drugs get axed by the FDA for reasons that won't apply here - i.e. - me too products, etc.

As you said - time will tell.